Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 360.5 JPY -0.63% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Olympus Corp?
Write Note

Olympus Corp
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Olympus Corp
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
PP&E Net
ÂĄ249.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
6%
Terumo Corp
TSE:4543
PP&E Net
ÂĄ412.2B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
9%
Sysmex Corp
TSE:6869
PP&E Net
ÂĄ113.6B
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
7%
Nihon Kohden Corp
TSE:6849
PP&E Net
ÂĄ26B
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
9%
JEOL Ltd
TSE:6951
PP&E Net
ÂĄ22.4B
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
6%
Fukuda Denshi Co Ltd
TSE:6960
PP&E Net
ÂĄ53.5B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
9%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.7T JPY
Industry
Health Care

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Intrinsic Value
2 766.08 JPY
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Olympus Corp's PP&E Net?
PP&E Net
249.5B JPY

Based on the financial report for Sep 30, 2024, Olympus Corp's PP&E Net amounts to 249.5B JPY.

What is Olympus Corp's PP&E Net growth rate?
PP&E Net CAGR 10Y
6%

Over the last year, the PP&E Net growth was -1%. The average annual PP&E Net growth rates for Olympus Corp have been 2% over the past three years , 4% over the past five years , and 6% over the past ten years .

Back to Top